SCHEMBL10258506

SCHEMBL10258506

CO/N=C(\COc1ccc(COc2ccc(/C=C/C(=O)O)c(OC)c2)cc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.56
PTPN1 P18031 1/20 0.50
MAPT P10636 2/20 0.49
ALDH1A1 P00352 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HDAC8 Q9BY41 2/20 0.48
APP P05067 1/20 0.47
PTGER4 P35408 3/20 0.46
PTGER2 P43116 3/20 0.46
PTGER3 P43115 3/20 0.46
PTGDR Q13258 1/20 0.46
PKM P14618 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
BLM P54132 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PPARG P37231 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15239336 1.00 FFAR1 (0.56) FFAR1PTPN1MAPTALDH1A1NPC1
SCHEMBL15239317 1.00 FFAR1 (0.56) FFAR1PTPN1MAPTALDH1A1NPC1
SCHEMBL15239318 1.00 FFAR1 (0.56) FFAR1PTPN1MAPTALDH1A1NPC1
SCHEMBL10260721 0.90 FFAR1 (0.52) FFAR1PTPN1MAPTALDH1A1NPC1
SCHEMBL22668030 0.90 FFAR1 (0.55) FFAR1PTPN1MAPTALDH1A1NPC1
SCHEMBL435344 0.88 FFAR1 (0.57) FFAR1PTPN1MAPTALDH1A1NPC1
SCHEMBL435343 0.88 FFAR1 (0.57) FFAR1PTPN1MAPTALDH1A1NPC1
SCHEMBL22668340 0.87 PTPN1 (0.52) PTPN1MAPTALDH1A1NPC1RAB9A
SCHEMBL22668359 0.87 FFAR1 (0.52) FFAR1PTPN1MAPTALDH1A1NPC1
SCHEMBL15239113 0.85 FFAR1 (0.63) FFAR1ALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 FFAR1 24/4885PTPN1 2995/4885MAPT 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.